Effects of Development on Olanzapine-Associated Adverse Events
- 1 December 2002
- journal article
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 41 (12) , 1439-1446
- https://doi.org/10.1097/00004583-200212000-00015
Abstract
No abstract availableKeywords
Funding Information
- Eli Lilly and Company and by NIH (grants MH54446 and MH61008 (S.W.W.), MH01792 (A.M.), and MH01654 (T.H.M.))
This publication has 44 references indexed in Scilit:
- Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in MoscowEuropean Psychiatry, 2000
- An open-label study of olanzapine in children with PDDSchizophrenia Research, 2000
- Olanzapine in the treatment of bipolar-disorder in juvenilesSchizophrenia Research, 2000
- Treatment of Childhood-Onset Schizophrenia with OlanzapineJournal of Child and Adolescent Psychopharmacology, 2000
- Elevated Prolactin in Pediatric Patients on Typical and Atypical AntipsychoticsJournal of Child and Adolescent Psychopharmacology, 1999
- Sources of Data for Pharmacoepidemiological Studies of Child and Adolescent Psychiatric DisordersJournal of Child and Adolescent Psychopharmacology, 1997
- Tardive Dyskinesia, Tardive Dystonia, and Tardive Tourette's Syndrome in Children and AdolescentsJournal of Child and Adolescent Psychopharmacology, 1993
- Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1988
- Neuroleptic-Induced Dyskinesias in ChildrenClinical Neuropharmacology, 1983
- Tardive Dyskinesia as a Possible Sequel of Long-Term Therapy with PhenothiazinesClinical Pediatrics, 1975